Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)

6 Months Ended

Dec. 31, 2021

Notes Tables

Schedule of Stockholders Equity [Table Text Block]

	Bio-Techne Shareholders
												Accumulated
							Additional					Other
	Common Stock						Paid-in		Retained			Comprehensive			Noncontrolling
	Shares			Amount			Capital		Earnings			Income(Loss)			Interest			Total
Balances at June 30, 2021		38,955		$	390		$	534,411	$	1,085,461		$	(57,291	)	$	8,263		$	1,571,234
Net earnings										69,615						(634	)		68,981
Other comprehensive income (loss)													(6,925	)		(39	)		(6,964	)
Share repurchases
Common stock issued for exercise of options		295			3			36,345		(13,481	)								22,867
Common stock issued for restricted stock awards		20			0			0		(9,765	)								(9,765	)
Cash dividends										(12,493	)								(12,493	)
Stock-based compensation expense								11,396											11,396
Common stock issued to employee stock purchase plan		3			0			1,358											1,358
Employee stock purchase plan expense								341											341
Balances at September 30, 2021		39,273		$	393		$	583,851	$	1,119,337		$	(64,216	)	$	7,590		$	1,646,955
Net earnings										80,173						(8,114	)		72,059
Other comprehensive income (loss)													4,742			66			4,808
Share repurchases		(89	)		(1	)				(41,293	)								(41,294	)
Common stock issued for exercise of options		134			1			18,604											18,605
Common stock issued for restricted stock awards		1
Cash dividends										(12,576	)								(12,576	)
Stock-based compensation expense								13,701											13,701
Common stock issued to employee stock purchase plan								6											6
Employee stock purchase plan expense								267											267
Balances at December 31, 2021		39,319			393			616,429		1,145,641			(59,474	)		(458	)		1,702,531

	Bio-Techne Shareholders
											Accumulated
					Additional						Other
	Common Stock				Paid-in			Retained			Comprehensive			Noncontrolling
	Shares		Amount		Capital			Earnings			Income(Loss)			Interest			Total
Balances at June 30, 2020		38,453	$	385	$	420,536		$	1,057,470		$	(97,199	)	$	-		$	1,381,192
Cumulative effect adjustments due to adoption of new accounting standards									(276	)								(276	)
Net earnings									33,395									33,395
Other comprehensive income (loss)												14,057						14,057
Common stock issued for exercise of options		117		1		13,727												13,728
Common stock issued for restricted stock awards		25		0		(0	)		(4,890	)								(4,890	)
Cash dividends									(12,336	)								(12,336	)
Stock-based compensation expense						12,667												12,667
Common stock issued to employee stock purchase plan		6		0		1,463												1,463
Employee stock purchase plan expense						286												286
Balances at September 30, 2020		38,601	$	386	$	448,679		$	1,073,362		$	(83,142	)	$	-		$	1,439,285
Non-controlling interest in Eminence															8,985			8,985
Net earnings									46,274						(130	)		46,144
Other comprehensive income (loss)												18,904			83			18,987
Common stock issued for exercise of options		161		2		16,748			(2,482	)								14,268
Common stock issued for restricted stock awards		3		0		(0	)		0									0
Cash dividends									(12,392	)								(12,392	)
Stock-based compensation expense						15,471												15,471
Employee stock purchase plan expense						106												106
Balances at December 31, 2020		38,765	$	388	$	481,004		$	1,104,762		$	(64,238	)	$	8,938		$	1,530,854

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

	Unrealized Gains (Losses) on Derivative Instruments			Foreign Currency Translation Adjustments			Total
Balance as of June 30, 2021	$	(6,193	)	$	(51,098	)	$	(57,291	)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne		1,682			(6,750	)		(5,068	)
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1)		2,884		$	-		$	2,884
Balance as of December 31, 2021(2)	$	(1,626	)		(57,848	)		(59,474	)

	Unrealized Gains (Losses) on Derivative Instruments			Foreign Currency Translation Adjustments			Total
Balance as of June 30, 2020 attributable to Bio-Techne	$	(13,253	)	$	(83,946	)	$	(97,199	)
Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne		(47	)		28,759			28,712
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne (3)		4,249			-			4,249
Balance as of December 31, 2020(2)	$	(9,051	)	$	(55,187	)	$	(64,238	)